Healthcare / BiotechnologyHKSE
$56.80
-1.10 (-1.90%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-290.6M · quality 51.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
12/100
SEC 0%
Sin guardar todavía.
Market Cap
$9.7B
P/E
N/A
•EV/EBITDA
N/A
•ROE
296.0%
↑Gross Margin
90.9%
↑Debt/Equity
-5.86
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2025 · 2 años de histórico normalizado
Revenue CAGR
+5709.7%
FCF CAGR
—
FCF margin
-195.7%
FCF / Net income
1.05x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $148.5M · net income $-278.1M · FCF $-290.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $148.5M | $148.5M | $142.6M | $44000.00 |
| Net Income | $-278.1M | $-278.1M | $-270.2M | $-428.3M |
| EBITDA | $-215.1M | $-215.1M | $-188.2M | $-366.8M |
| EPS | — | — | -1.67 | -2.65 |
| Gross Margin | 90.9% | 90.9% | 91.7% | 45.5% |
| Operating Margin | -169.0% | -169.0% | -158.7% | -844711.4% |
| Net Margin | -187.2% | -187.2% | -189.4% | -973520.5% |
| Balance Sheet | ||||
| Debt/Equity | -5.86 | -5.86 | -3.89 | 3.95 |
| Current Ratio | 0.86 | 0.86 | — | — |
| Cash Flow | ||||
| Free Cash Flow | $-290.6M | $-290.6M | $-84.1M | $-328.2M |
| Returns | ||||
| ROE | 296.0% | 296.0% | 244.8% | -407.6% |
| Growth & Yield | ||||
| Revenue Growth | 4.1% | 4.1% | 324052.3% | — |
| EPS Growth | — | — | 36.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-30.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.67 → n/d
Residual
-30.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.